The presentation will assist pharmacists in evaluating the most recent guideline update an emerging treatments. This will help pharmacists make recommendations and changes to therapy in line with current evidenced based practices. The purpose of the session is to review recent guideline updates by the American Heart Association/American College of Cardiology. The goal of the session is to augment pharmacist understanding of treatment and management of blood pressure. The knowledge and skills to be gained from the session is utilization of relevant risk calculators to guide treatment, patient education on at home Blood pressure monitoring, and effective management of blood pressure treatment, including medications in the pipeline.

Learning Objectives

At the completion of this session, pharmacists will be able to:
1. Given a patient case with either newly diagnosed hypertension, follow-up, or a hypertensive emergency, design a patient-centered plan that incorporates pharmacologic and non-pharmacologic 2025 Hypertension guideline recommendations. 
2. Summarize the significant additions to the 2025 Hypertension guideline recommendations. 
3. Identify emerging antihypertensive therapies and drugs in the pipeline, and assess their potential role in future patient care.

At the completion of this session, technicians will be able to:
1. Summarize the significant additions to the 2025 Hypertension guideline recommendations. 
2. Identify emerging antihypertensive therapies and drugs in the pipeline, and their potential role in future patient care.

Texas Pharmacy Association (154) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Continuing education will be provided to participants who completed all course requirements.
ACPE 0154-0000-26-005-H01-P
ACPE 0154-0000-26-005-H01-T
1 Contact Hour (0.1 CEU)
Knowledge-based